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SUMMARY 
Early second-trimester oligohydramnios was associated with normal maternal serum alpha- 
fetoprotein (MSAFP) levels in nine out of 26 cases (35 per cent). Congenital malformations of 
the fetal urinary tract resulting in fetal anuria were present in nine cases; in seven of them, 
normal MSAFP levels were measured. In contrast, normal MSAFP levels were established in 
only 2 out of the 17 cases without fetal malformations. These data suggest that fetal urine is 
the major source of elevated AFP in the maternal compartment in early second-trimester 
oligohydramnios. This is further supported by the lack of any relationship between concen- 
trations of MSAFP non-reactive with Concanavalin A, originating mainly from the yolk sac- 
derived amniotic fluid AFP pool, and the presence of fetal diuresis. Three out of 26 women 
had experienced early second-trimester oligohydramnios in a previous pregnancy, suggesting 
the existence of a recurrence risk for this condition. 
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INTRODUCTION 
Various reports have appeared on the association between raised levels of maternal 
serum alpha-fetoprotein (MSAFP) and early second-trimester oligohydramnios 
(Dyer el ul., 1987; Richards et al., 1988; Kelly et al., 1989). Dericks-Tan et al. (1982) 
established raised MSAFP concentrations in women suffering from rupture of the 
fetal membranes prior to 20 weeks of gestation. 
Recently it has been shown that AFP in amniotic fluid is the source of the rise in 
MSAFP levels in second-trimester oligohydramnios, probably due to a defect in the 
fetal membranes (Los et al., 1992). This report also documented normal MSAFP 
levels in early second-trimester oligohydramnios in three cases, of which two had 
malformations of the fetal urinary tract, causing fetal anuria or  oliguria. In this 
study of an extended series of women with early second-trimester oligohydramnios, 
we report the finding of normal MSAFP levels, especially in the presence of con- 
genital malformations of the fetal urinary tract resulting in fetal oliguria or anuria. 
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MATERIALS AND METHODS 
Between September 1988 and May 1991, 29 women with early second-trimester 
oligohydramnios were detected among 3300 pregnant women referred for ultra- 
sound investigation to the prenatal diagnostic centre of the University Hospital 
Dijkzigt, Rotterdam. Gestational age varied between 15 and 20 weeks (median 18 
weeks). Ultrasound investigation involved two-dimensional real-time assessment of 
fetal size and structure, placental localization, and amniotic fluid volume. A linear 
array two-dimensional real-time system (Toshiba SSA-270A, 3.75 MHz) was used. 
Oligohydramnios was diagnosed when the largest pocket of amniotic fluid measured 
up to 2 cm (Los et al., 1992). 
Blood samples for MSAFP measurement of 26 of these 29 women were spun 
down twice, and the sera stored at -20°C until assay. MSAFP concentrations 
were measured with a polyclonal enzyme-linked immunosorbent assay (ELISA) 
(Los et al., 1989). The cut-off level of 2.5 multiples of the median value (MOM) was 
used for the definition of raised MSAFP levels (U.K. Collaborative Study, 1977), 
representing the 97th centile (Los et al., 1992). 
Measurement of non-Concanavalin A-reactive MSAFP concentrations was 
carried out as described previously with a three-stage monoclonal antibody ELISA 
(Marrink et al., 1990; Los et al., 1992). 
Fetal birth weights were related to reference weight for gestation figures according 
to Exalto (1979) up to 19 weeks and according to Kloosterman (1970) for the 
remainder of the pregnancy. 
The Wilcoxon rank sum test was applied for comparison of MSAFP levels in 
women carrying normal fetuses and those carrying fetuses with congenital 
anomalies of the urinary tract. Distribution frequencies of normal versus abnormal 
MSAFP levels in relation to normal or abnormal fetal outcome were studied with 
the Fisher exact test, and of fetal sex with binomial statistics. 
RESULTS 
Congenital malformations were diagnosed in 9 out of 26 women with oligo- 
hydramnios. All anomalies were related to the fetal urinary tract, and were 
confirmed by necropsy (Table 1). Of the 17 cases without fetal abnormalities, 14 
were confirmed by necropsy; in two cases, no post-mortem examination was carried 
out and in one case, a live infant was born (Table 2). Two fetuses were severely 
growth-retarded as established by ultrasound (cases 25 and 26, Table 2). In three 
instances, the fetus displayed undetected moderate growth retardation (cases 14, 19, 
and 20, Table 2). 
MSAFP concentrations ranged between 39 and 272 pg/l (median 158 pg/l) in the 
group without fetal anomalies, and between 47 and 157 pg/l (median 88 pg/l) in the 
group with fetal urinary tract malformations. This difference in level is statistically 
significant (Wilcoxon rank sum test,p <0.01). Normal MSAFP levels were found in 
9 out of 26 women (35 per cent), seven of which carried a fetus with urinary tract 
anomalies (Figure 1). The remaining two fetuses were normal (cases 16 and 26, 
Table 2). In the 17 women (65 per cent) with raised MSAFP levels, only two carried a 
fetus with a urinary tract malformation (cases 1 and 4, Table 1; Figure 1). This 
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Table 1. Ultrasound diagnosis and post-mortem findings in the nine women with fetal malfor- 
mations. Classification of cystic kidneys (types I-IV) according to Zerres er al. (1984) 
~~ ~ 
Weeks of UI trasound 
Case gestation findings Fetal outcome 
1 19 
2 18 
3 20 
4 16 
S 17 
6 20 
7 19 
8 16 
9 18 
Spina bifida, hydrocephaly, 
bilateral renal agenesis 
Enlarged urinary bladder, 
bilateral hydronephrosis 
Multicystic kidneys, no 
bladder filling 
Enlarged urinary bladder, 
bilateral hydronephrosis 
Enlarged urinary bladder, 
hydronephrosis (left) 
Multicystic kidney (right), 
renal agenesis (left), no 
bladder filling 
Bilateral renal agenesis, no 
bladder filling 
Renal dysplasia/agenesis, no 
bladder filling 
Bilateral renal agenesis, no 
bladder filling 
TOP, 19.5 weeks, 0 ,  250 g, spina 
bifida, bilateral renal agenesis, 
46,XX 
TOP, 19 weeks, $, 600 g, distal 
urethral obstruction, distended 
bladder, cystic kidneys type IV, 
46.XY 
TOP, 20.5 weeks, 6, cystic 
kidneys type I1 B, 46,XY 
TOP, 19 weeks, Q, urethral 
agenesis, distended bladder, 
hydronephrosis, 46,XX 
TOP, 19 weeks, $, 295 g, 
urethral hypoplasia, dilated 
bladder, hydronephrosis, 46,XY 
TOP, 20 weeks, 6, 260 g, cystic 
kidney type I1 A (right), renal 
agenesis (left), rocker bottom 
feet, ulnar deviation of dig. 
11-IV, trisomy 11 (q21 -+qter)* 
TOP, 19 weeks, 6,250 g, 
bilateral renal agenesis, 
syndactyly, cryptophthalmus 
(phenotype 219000; McKusick, 
1990), 46,XY 
TOP, 17 weeks, $, 125 g, 
hypoplastic ureter and cystic 
kidney type IV (right), renal 
agenesis (left) 
TOP, 19 weeks, 8,  bilateral renal 
agenesis, 46,XY 
TOP = Termination of pregnancy. 
*Fetal karyotype: 46,XY, - 8,+ rec (8) (8qter-8p23::l lq21- 1 Iqter),t(l;l 1)mat. Maternal karyo- 
type: 46,XX,t(8;11)(8q12+8p23::1 lq21-+ I1qter;l lpter-1 lq21::8ql2-.8qter)mat. 
difference in the incidence of fetal urinary tract anomalies between the group with 
normal and the  group with raised MSAFP levels is statistically significant (Fisher 
exact test, p = 0.001 6). 
Concentrations of non-Concanavalin A-reactive MSAFP ranged between 2 and 
12 pg/l (median 7 pg/l) in the 17 women without fetal malformations, and between 4 
and 9 pg/l (median 6 pg/1) in the nine women with fetal urinary tract anomalies 
(Figure 2). This difference is not statistically significant (Wilcoxon rank sum test, 
0.05 < p  < 0.95). 
Fetal sex was female in six and male in 20 cases; this gender distribution towards a 
male fetal outcome was statistically significant (binomial statistics, p = 0.0047). 
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Table 2. Ultrasound diagnosis and fetal outcome in 17 women with early second-trimester 
oligohydramnios without fetal malformations 
Additional 
Weeks of ultrasound 
Case gestation findings Fetal outcome 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
19 
18 
16 
20 
18 
16 No additional 
16 findings 
15 
16 
19 
17 
20 
18 
20 
17 Increase in A F  
volume after 20 weeks 
18 Signs of IUGR 
19 Signs of IUGR 
IUD, 24 weeks, 8, 440 g, 46,XY 
PD, 22 weeks, 8,440 g, tpp, 46,XY 
IUD, 18 weeks, 8, no necropsy 
PD, 26 weeks, 6 ,  745 g, tpp 
IUD, 20 weeks, 8, 160 g 
IUD, 17 weeks, 6,210 g 
TOP, 17 weeks, 0, 150 g, 46,XX 
TOP, 19.5 weeks, 6, 265 g 
IUD, 22 weeks, 6,370 g 
IUD, 20 weeks, 8, 200 g, no necropsy 
IUD, 17 weeks, 8, 100 g 
IUD, 22 weeks, 0,380 g 
TOP, 22 weeks, ? ,3  10 g, 46,XX 
PD, 25 weeks, d, 830 g, tpp, 46,XY 
PD, 35 weeks, 8,2230 g, lung 
hypoplasia, postural deformities; 
presently well 
IUD, 22 weeks, 6, 100 g 
TOP, 20 weeks, ?,65 g, 46,XX 
AF= Amniotic fluid; IUGR = intrauterine growth retardation; TOP = termination of pregnancy; 
PD = premature delivery; t p p  = fetal death post-partum; IUD =intrauterine death. 
Twenty-two out of 26 women were multigravidae, seven of whom displayed a 
fetal urinary tract anomaly. Three out of these seven women had experienced the 
same fetal anomaly in a previous pregnancy. In one of these women (case 5, Table l) ,  
there had also been early second-trimester oligohydramnios and a male fetus; in the 
other two women (cases 7 and 8, Table l), there had only been late second- and third- 
trimester oligohydramnios. In the remaining 15 women without a fetal anomaly, 
two had experienced early second-trimester oligohydramnios in  a previous preg- 
nancy. In both instances, a male fetus was delivered (cases 19 and 21, Table 2). 
DISCUSSION 
Normal MSAFP levels were measured in 9 out of 26 women with early second- 
trimester oligohydramnios (35 per cent). In seven of these nine women, congenital 
malformations of the fetal urinary tract, resulting in fetal anuria or oliguria, were 
present. Fetal anuria has been suggested to be one of the predisposing factors for 
damage of the fetal membranes with subsequent early second-trimester oligo- 
hydramnios (Los et af., 1992). Second-trimester oligohydramnios associated with 
raised MSAFP levels occurred in only two of the nine women with fetal anuria. 
Normal fetal diuresis therefore seems to be the major source of the raised MSAFP 
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Figure 1. Levels of  total MSAFP (MOM). Open circles/squares denote female/male fetuses without 
congenital malformations; closed signs, those with congenital malformations 
levels in this condition, assuming that diuresis was normal in the presence of a 
normal fetus. 
Amniotic fluid AFP originates from different sources: fetal urine, secretions from 
the fetal gastrointestinal and respiratory tracts, diffusion across the fetal skin, and 
from the fetal vessels in the umbilical cord and chorionic plate (Sutcliffe, 1975; 
Ruoslahti and Seppala, 1979). A further source during the first trimester of preg- 
nancy is the yolk sac, contributing especially non-Concanavalin A-reactive AFP to 
the amniotic fluid AFP pool (Ruoslahti et al., 1978). 
Fetal urine is considered to be the major source of amniotic fluid AFP (Brock, 
1976). However, fetal anuria would have little effect on the non-Concanavalin 
A-reactive AFP pool of amniotic fluid as the fetal compartment contributes only a 
low percentage of non-Concanavalin A-reactive AFP to amniotic fluid (Ruoslahti 
el al., 1978; Toftager-Larsen, 1990). The difference in median total and non- 
Concanavalin A-reactive MSAFP concentrations of 70 pg/l (1 58 minus 88) and 
1 pg / l (7  minus 6) between the groups with and without fetal anomalies is compatible 
with the lack of an AFP source containing a low percentage of non-Concanavalin A- 
reactive AFP in fetal anuria. 
A reduced fetal weight for gestational age was observed in five fetuses, all 
without fetal malformations. Early intrauterine growth retardation is known to be 
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Figure 2. Concentrations of non-Concanavalin A-reactive MSAFP (ug/l). See legends of Figure 1 for 
meaning of symbols 
associated with second-trimester oligohydramnios due to reduced fluid supply to the 
amniotic fluid compartment (Hackett et al., 1987). Damage to the fetal membranes 
might occur in the same way as in fetal anuria (Los et al., 1992). 
A qualitative model for feto-maternal AFP transfer in the normal situation and 
in early second-trimester oligohydramnios is presented in Figure 3. In this 
compartment-barrier model, AFP transfer is assumed to be a passive process 
according to AFP concentration gradients from the fetus to the mother, from the 
fetus to the amniotic fluid compartment, and from the amniotic fluid compartment 
to the mother across various membranes or barriers. A breakdown of a barrier 
results in higher AFP concentrations, and the absence of a barrier (infinite resistance 
for AFP transfer) in lower AFP concentrations in the distal compartment(s). The 
absence of the fetal urinary tract barrier between the fetus and the amniotic fluid 
compartment, or decreased fluid supply to the amniotic fluid in the case of intra- 
uterine growth retardation, diminishes the amniotic fluid compartment with 
subsequent breakdown of the barrier between the amniotic fluid compartment and 
the mother (fetal membranes). Mechanical damage of this barrier has been 
suggested in early second-trimester oligohydramnios following threatened abortion 
or intrauterine instrumentation (Los et al., 1992). 
MATERNAL SERUM ALPHA-FETOPROTEIN LEVELS 29 1 
3 FETUS 
PLACENTA 
FETUS 
YOLK 
SAC PLACENTA 
+ 1 1 FETUS I PLACENTA I 
MOTHER I 
5 12 WEEKS 2 16 WEEKS OLIGOHYDRAMNIOS 
Figure 3. Compartment-barrier model for feto-maternal AFP transfer. On the left: situation before 12 
weeks of gestation; in the middle: situation from 16 weeks of gestation onwards, after fusion of decidua 
parietalis and capsularis; on the right: situation in early second-trimester oligohydramnios. 1 =Placental 
barrier between the fetus and mother; 2 =  barriers between the fetus and amniotic fluid (fetal skin; 
urinary, gastrointestinal, and respiratory tracts; umbilical cord; and part of chorionic plate occupied by 
fetal vessels); 3 =barrier between amniotic fluid and mother (fetal membranes and part of chorionic plate 
not occupied by fetal vessels); 4 =barrier between yolk sac (extraembryoniccoelomic space) and amniotic 
fluid; 5 =barrier between yolk sac (extraembryonic coelomic space) and mother (chorionic plate before 
fusion of amnion and chorion) 
In the present study, fetal outcome was predominantly male both in the presence 
and in the absence of fetal malformations. This suggests that fetal membranes of 
male origin may be less resistant to damage than those of female origin. This has to 
be further substantiated. 
Early second-trimester oligohydramnios seems to be a particular problem in 
multigravidae. Our data indicate a recurrence risk of early second-trimester 
oligohydramnios in both fetuses with and without urinary tract abnormalities. The 
finding of a normal MSAFP level in early second-trimester oligohydramnios 
strongly suggests fetal urinary tract pathology. 
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